Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(178.88% Upside)
| Highest Price Target$35.00 | Average Price Target$35.00 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$35
Buy
178.88%
Upside
Reiterated
11/17/25
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary DiseasesValuation and Risks. Our Buy rating and $35 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2038 and assign a 15% discount rate and 0% terminal growth rate, given that we view MiNK’s technology as a platform. We currently assume value for AGENT-797 for treatment of NSCLC with 10% POS and gastric cancer with 15% POS, and have not included other pipeline assets or indications in our valuation.
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$35
Buy
178.88%
Upside
Reiterated
11/17/25
MiNK Therapeutics: Advancing Clinical Trials and Strategic Partnerships to Address GvHD and Pulmonary DiseasesValuation and Risks. Our Buy rating and $35 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2038 and assign a 15% discount rate and 0% terminal growth rate, given that we view MiNK’s technology as a platform. We currently assume value for AGENT-797 for treatment of NSCLC with 10% POS and gastric cancer with 15% POS, and have not included other pipeline assets or indications in our valuation.
Best Analysts Covering MiNK Therapeutics
1 Month
xxx
Success Rate
6/17 ratings generated profit
Average Return
-1.87%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.29% of your transactions generating a profit, with an average return of -1.87% per trade.
3 Months
xxx
Success Rate
7/17 ratings generated profit
Average Return
+16.10%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 41.18% of your transactions generating a profit, with an average return of +16.10% per trade.
1 Year
Success Rate
8/17 ratings generated profit
Average Return
+71.34%
reiterated a buy rating 27 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +71.34% per trade.
2 Years
xxx
Success Rate
9/17 ratings generated profit
Average Return
+99.15%
reiterated a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 52.94% of your transactions generating a profit, with an average return of +99.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INKT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jul 25
Aug 25
Nov 25
Strong Buy
2
2
1
3
4
Buy
1
2
2
2
1
Hold
5
6
5
5
4
Sell
3
3
1
0
0
Strong Sell
0
0
0
0
0
total
11
13
9
10
9
Each month's total comprises the sum of three months' worth of ratings.
INKT Financial Forecast
INKT Stock Forecast FAQ
What is INKT’s average 12-month price target, according to analysts?
Based on analyst ratings, MiNK Therapeutics’s 12-month average price target is 35.00.
What is INKT’s upside potential, based on the analysts’ average price target?
MiNK Therapeutics has 178.88% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INKT a Buy, Sell or Hold?
MiNK Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is MiNK Therapeutics’s price target?
The average price target for MiNK Therapeutics is 35.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $35.00. The average price target represents 178.88% Increase from the current price of $12.55.
The highest analyst price target is $35.00 ,the lowest forecast is $35.00. The average price target represents 178.88% Increase from the current price of $12.55.
What do analysts say about MiNK Therapeutics?
MiNK Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of INKT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.